Latest news
Explained: Risks to assess before investing in small and mid-capsAcross the spectrum: What UT’s leaders said after meetClaims throw light on insurance status: Only 14% of Covid deaths had coverRIL to invest Rs 75,000 crore in new energy biz over next 3 yrsBetter GST mop-up likely: In 20 days, June e-way bills rise 34% over month agoTelangana: Scheduled Castes panel sends notice to DGP, Chief Secy over custodial deathMaoists confirm two Covid-19 deaths among its senior cadresMan killed while ‘out hunting’ in Latehar, cops claim ‘cross-fire’Karnataka ‘honour killing’: Dalit youth, Muslim girl stabbedBelagavi ‘missing’ gold case: CID asks cops to join probeMamata writes to PM Modi for expediting WHO nod to CovaxinFIR against The Wire, 3 journalists for video on Barabanki mosque demolitionMamata plea to recuse: Calcutta HC judge reserves order, refers to ‘media trial’Explained: Vaccine makers and indemnity
Advertisement

Sputnik V vaccine for Covid-19 to be priced at Rs 995 in India; first dose administered in Hyderabad

Dr Reddy's administered the first shot of Russia's Sputnik V vaccine for Covid-19 in Hyderabad on Friday.

Russia has observed a spike in Coronavirus cases with infections doubling in Moscow. (File Photo)

Dr Reddy’s on Friday administered the first shot of Russia’s Sputnik V vaccine for Covid-19 in Hyderabad. The company said the imported vaccines would be priced at Rs 995.40 (Rs 948 + 5 per cent GST). The price may reduce when local supply begins.

Dr Reddy’s said it was working with six manufacturers in India to fulfill regulatory requirements to ensure smooth and timely supply of the vaccine.

The company, in a statement, said the first dose was administered as part of a limited pilot. “Further consignments of imported doses are expected over the upcoming months. Subsequently, supply of Sputnik V vaccine will commence from Indian manufacturing partners,” it said.

https://images.indianexpress.com/2020/08/1x1.png

Sputnik V, the vaccine developed by Russia, is now the third coronavirus vaccine to get emergency use approval, after Covishield (Serum Institute of India) and Covaxin (Bharat Biotech).

Phase 3 trials of the vaccine, conducted in Russia, have found it has an efficacy of 91.6 per cent.

Explained |How Sputnik V works against novel coronavirus, and how effectively

The vaccine, developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, uses two different viruses that cause the common cold (adenovirus) in humans. The adenoviruses are weakened so they cannot replicate in humans and cannot cause disease. They are also modified so that the vaccine delivers a code for making the coronavirus spike protein. This aims to ensure that when the real virus tries to infect the body, it can mount an immune response in the form of antibodies.

The Russian Direct Investment Fund (RDIF) had partnered with Dr Reddy’s in September 2020 to conduct clinical trials in India.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

News Assist
ePaper
Next Story
X
X